Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura J Esserman

Showing results (261-270 of 308) with videos related to

Pageof 31
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2012
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657Laura J Esserman, Donald A Berry, Angela DeMichele, et al.
Annals of Surgical Oncology|July 12, 2024
Clipping the Positive Lymph Node in Patients with Clinically Node Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical TrialKayla M Switalla, Judy C Boughey, Katrina Dimitroff, et al.
Nature Communications|December 9, 2025
Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumorsMark Jesus M Magbanua, Nayelis A Manon, Denise M Wolf, et al.
Cell Reports. Medicine|December 12, 2023
Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 TrialRosa I Gallagher, Julia Wulfkuhle, Denise M Wolf, et al.
Breast Cancer Research and Treatment|January 23, 2023
Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT studyMark Jesus M Magbanua, Laura van 't Veer, Amy S Clark, et al.
Annals of Surgery|June 16, 2023
Breast Conservation Surgery and Mastectomy Have Similar Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From 1462 Patients on the Prospective, Randomized I-SPY2 TrialRita A Mukhtar, Harrison Chau, Hannah Woriax, et al.
Breast Cancer Research : BCR|September 13, 2017
Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumorsImke H Bartelink, Brendan Prideaux, Gregor Krings, et al.
JAMA Ophthalmology|December 4, 2025
Multicenter Interspecialty Consensus on Experimental Oncology Drug-Related Ocular Adverse Event ReportingNeel D Pasricha, Stella K Kim, Asim V Farooq, et al.
Nature Reviews. Clinical Oncology|July 1, 2020
Publisher Correction: Personalized early detection and prevention of breast cancer: ENVISION consensus statementNora Pashayan, Antonis C Antoniou, Urska Ivanus, et al.
Nature Reviews. Clinical Oncology|June 20, 2020
Personalized early detection and prevention of breast cancer: ENVISION consensus statementNora Pashayan, Antonis C Antoniou, Urska Ivanus, et al.
Pageof 31

Showing results (261-270 of 308) with videos related to

Sort By:
Pageof 31
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2012
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657Laura J Esserman, Donald A Berry, Angela DeMichele, et al.
Annals of Surgical Oncology|July 12, 2024
Clipping the Positive Lymph Node in Patients with Clinically Node Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical TrialKayla M Switalla, Judy C Boughey, Katrina Dimitroff, et al.
Nature Communications|December 9, 2025
Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumorsMark Jesus M Magbanua, Nayelis A Manon, Denise M Wolf, et al.
Cell Reports. Medicine|December 12, 2023
Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 TrialRosa I Gallagher, Julia Wulfkuhle, Denise M Wolf, et al.
Breast Cancer Research and Treatment|January 23, 2023
Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT studyMark Jesus M Magbanua, Laura van 't Veer, Amy S Clark, et al.
Annals of Surgery|June 16, 2023
Breast Conservation Surgery and Mastectomy Have Similar Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From 1462 Patients on the Prospective, Randomized I-SPY2 TrialRita A Mukhtar, Harrison Chau, Hannah Woriax, et al.
Breast Cancer Research : BCR|September 13, 2017
Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumorsImke H Bartelink, Brendan Prideaux, Gregor Krings, et al.
JAMA Ophthalmology|December 4, 2025
Multicenter Interspecialty Consensus on Experimental Oncology Drug-Related Ocular Adverse Event ReportingNeel D Pasricha, Stella K Kim, Asim V Farooq, et al.
Nature Reviews. Clinical Oncology|July 1, 2020
Publisher Correction: Personalized early detection and prevention of breast cancer: ENVISION consensus statementNora Pashayan, Antonis C Antoniou, Urska Ivanus, et al.
Nature Reviews. Clinical Oncology|June 20, 2020
Personalized early detection and prevention of breast cancer: ENVISION consensus statementNora Pashayan, Antonis C Antoniou, Urska Ivanus, et al.
Pageof 31